A new drug for small cell lung cancer——Tarlatamab
10.13699/j.cnki.1001-6821.2024.24.024
- VernacularTitle:治疗小细胞肺癌新的药物——Tarlatamab
- Author:
Ming-xin GUO
1
;
Wen-tong FANG
;
Wei-min WANG
;
Zhi-qiang HU
;
Li-min ZHOU
Author Information
1. 江苏大学附属宜兴医院药学部,江苏宜兴 214200
- Publication Type:Journal Article
- Keywords:
Tarlatamab;
small cell lung cancer;
bispecific T cell adapter protein;
delta-like ligand 3;
immunotherapy
- From:
The Chinese Journal of Clinical Pharmacology
2024;40(24):3640-3642
- CountryChina
- Language:Chinese
-
Abstract:
Tarlatamab is a bispecific T cell adapter protein(BiTE)antibody that targets delta-like ligand 3(DLL3)on the surface of small cell lung cancer(SCLC)cells and CD3 on the surface of T cells,allowing them to approach and activate the T cell-mediated death of cancer cells.Clinical study data show that Tarlatamab has strong anti-tumor efficacy and is safe for the treatment of SCLC.The US Food and Drug Administration(FDA)has granted priority clearance to the licensing application for Tarlatamab,a biological drug intended to treat adult patients with advanced SCLC who progress during or after platinum treatment.Tarlatamab will be the first bi-targeted treatment for large solid tumors.This page introduces Tarlatamab's mechanism of action,pharmacokinetics,usage and dosage,clinical research,and safety.
